INTRODUCTION
The BRAF proto-oncogene encodes a serine/threonine kinase belonging to the raf/mil family. The BRAF protein resides at the apex of, and thus provides a critical regulatory function for, the mitogen-activated kinase (MAPK) signaling cascade. The most frequent somatic alteration in the BRAF gene is a point mutation in codon 600 that replaces valine with glutamate Colorectal carcinomas (CRCs) that harbor the BRAF V600E mutation are a distinct subset of tumors. They are frequently associated with poor differentiation, mucinous histology and advanced TNM stage (3) . In patients with microsatellite-stable CRC (4, 5) and those with advanced CRC (6), BRAF V600E mutation confers worse survival compared to their wild-type counterpart. PMS2 proteins by immunohistochemistry (IHC) also harbors BRAF V600E mutation (7) .
BRAF V600E mutation confers important predictive value in the treatment of patients with CRCs. Some clinical studies, supported by in vitro results (8) , have reported a detrimental effect of BRAF V600E mutation in patients with CRC treated with the anti-epidermal growth factor receptor therapy cetuximab or panitumunab (9) (10) (11) (12) , although data are conflicting. In a subsequent analysis of pooled data from the randomized phase III trial, Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer (CRYSTAL), and the randomized phase II trial, Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer (OPUS), no significant differences in outcome (overall survival, progression-free survival and best overall response rate) were found between CRC patients with BRAF mutations and BRAF wildtype (13) . In vitro and in vivo xenograft models have shown that CRC that harbor More recently, a mouse monoclonal antibody for the BRAF V600E protein (clone VE1, Spring Bioscience, Pleasanton, CA) has become commercially available for use in IHC. This method has the advantages of being relatively fast, inexpensive, and widely available for use in routine formalin-fixed, paraffinembedded tissue. In addition, IHC overcomes numerous challenges associated with sequence analysis that include limited availability of the technology, requirement for larger tumor sample, and effects of dilution with non-neoplastic tissue.
Previous studies on the suitability of VE1 IHC for the detection of BRAF V600E mutation in CRC found sensitivity ranging from 59% to 100% and specificity ranging from 51% to 100% with use of different IHC techniques, including a wide spectrum of antibody conditions, and different sequencing techniques as the comparator (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . In the largest such series to date, investigators used whole tissue sections to analyze 113 BRAF wild-type and 52 BRAF V600E-mutated CRCs in the validation cohort (21) and reported sensitivity of 96% and specificity of 99%. Despite these reportedly high concordances between results of VE1 IHC and sequence analysis, in our clinical practice we had noted discordances between VE1 IHC and sequencing results when both tests were performed on CRC samples. In contrast, concordance was high between results of the two tests in melanoma and papillary thyroid carcinoma samples. Because VE1 IHC has been proposed for use as a surrogate marker for BRAF V600E mutation-even replacing molecular studies altogether-we believed that more rigorous validation of VE1 IHC with a large cohort of patients 
MATERIALS AND METHODS

Study population
The pathology files of The University of Texas MD Anderson Cancer
Center were searched for all resection specimens of CRC (primary tumors and metastases) from 2008 through 2013 for which BRAF mutation analysis had been performed. As previously published studies have reported sensitivity and specificity of up to 100% for VE1 IHC, we planned to analyze a sample size of at least 300 cases each of BRAF wild-type CRC and BRAF V600E CRC so that 100% concordance between sequencing and IHC would give us an upper 95% confidence boundary of less than 1% discordance. We therefore randomly selected for inclusion in this study a total of 323 CRC cases to include equal numbers of cases each year from over 1500 CRC cases that had no mutation detected in the BRAF gene (wild-type) by sequencing and that had available material for IHC testing. other than V600E on sequencing that had residual material available to perform IHC; all of these cases were included in this study. Thus, a total of 480 CRCs were analyzed with VE1 IHC, as described below.
For comparison, we also searched our pathology files to identify cases of melanoma and papillary thyroid carcinoma that had already been analyzed for BRAF V600E mutation by both sequence analysis and VE1 IHC in 2013 and 2014. For these cases, we abstracted the previously recorded findings on sequence analysis and VE1 IHC from patient records. VE1 cytoplasmic staining was scored microscopically at the time of the study by semiquantitative analysis by one pathologist (JSE) according to the following scoring system: 0, negative; 1, weak staining in <20% of tumor cells (Fig. 1A) ; 2, moderate to strong staining in <20% of tumor cells (Fig. 1B) 
Statistical analysis
Sensitivity was defined as the ratio of true positives on VE1 IHC to positives identified by BRAF sequencing, and specificity was defined as the ratio of true negatives on VE1 IHC to negatives on sequencing, both expressed as percentage. Spearman's rho (ρ) was calculated to assess the nonparametric correlation between VE1 IHC results and results of the different sequencing methods.
RESULTS
Study population
The characteristics of patients included in the study are summarized in Table 1 . The 15 BRAF mutations other than V600E identified by sequencing were as follows: D594G (6), K601E (2), G464V (1), G466V (1), G466E (1), Approximately equal numbers of BRAF wild-type cases had been analyzed with one of the three sequencing techniques, since BRAF wild-type cases were randomly selected to include an equivalent number of cases from each year of the study. In contrast, most (63%) of the tumors with a BRAF mutation, including both V600E and mutations other than V600E, had been identified using pyrosequencing. The percentage of BRAF mutation by pyrosequencing was 49% (99/202); by Sequenom, 28% (41/148); and by NGS, 13% (17/130). These data highlight an important limitation in that the relative frequency of mutation may be dependent upon the methodology employed.
Additional studies are warranted to determine the most appropriate gold standard for comparison to IHC, although, these additional studies are beyond the scope of the current study. As a result of these findings, however, the Bond immunohistochemistry method was evaluated in relation to the individual sequencing methods, as well as to all three sequencing methods combined.
VE1 IHC using the Bond method in all CRC
Results of VE1 IHC using the Bond method are tabulated in Supplementary Table S1 . Among the 142 CRC cases that had a BRAF V600E mutation by sequence analysis, 77 cases (54%) had cytoplasmic staining in Table 2 . The definition yielding the highest sensitivity and specificity was staining in ≥20% of tumor cells regardless of intensity, which we applied in the subanalysis below.
Non-specific staining was frequently seen in both BRAF wild-type and Figure S1 ) and included the following patterns: weak to strong nuclear and cytoplasmic staining of histopathologically normal colonic mucosa and inflammatory cells; weak to strong granular cytoplasmic staining of smooth muscle in muscularis mucosae, muscularis propria, and thick-walled blood vessels; strong staining of luminal mucin; and 
BRAF-mutated cases (Supplementary
VE1 IHC using the Bond method in comparison to sequencing method
The sensitivity and specificity of VE1 IHC using the Bond method and applying the definition of positive staining as cytoplasmic staining in ≥20% of tumor cells are summarized in Table 3 according to the BRAF sequencing technique that was used. For all three sequencing techniques, the majority of CRC cases with BRAF V600E identified by sequencing was positive by VE1 IHC in ≥20% of tumor cells; specificities ranged from 89% to 95%. However, for each sequencing technique, some cases identified as positive for BRAF V600E were negative by VE1 IHC; sensitivities ranged from 70% to 84%. The relatively low sensitivity of VE1 IHC to detect BRAF V600E has great potential clinical impact, as this finding indicates that some CRC cases with BRAF V600E mutation would be missed if only IHC were used as the method of detection.
Among 36 cases with BRAF V600E mutation by sequence analysis but negative cytoplasmic staining (scores 0 and 1) on VE1 IHC (Supplementary   Table S1 ), BRAF mutation status in the majority of cases was determined by pyrosequencing (27 cases, 75%). One possible explanation for the discordance was that pyrosequencing may have erroneously detected the BRAF V600E mutation. Indeed, comparison of VE1 IHC results against pyrosequencing results yielded the lowest correlation coefficient (ρ=0.487, Table 3 ) and the lowest sensitivity (70%) and specificity (89%). We attempted to repeat BRAF mutation We reviewed the sequencing result of 18 cases with BRAF V600E mutation but negative (score 0) VE1 IHC by the Bond method to determine the mutation signal of these cases. Among 18 cases, 17 (94%) were definitive for the BRAF V600E mutation with allele burden ranging from 10%-60% (median = 30%). In one case, there is a low level mutation (allele burden = 6%); however, repeat testing yielded the same result.
Among the 13 cases that were BRAF wild-type by sequence analysis but had moderate to strong cytoplasmic staining in ≥20% of tumor cells (scores 4 and 6) on VE1 IHC (Supplementary Table S1 ), BRAF mutation status had been 
discordance was that the tissue was amenable to IHC studies, whereas DNA isolated from the tumor was suboptimal for molecular testing. However, in 9 of 13 cases, molecular testing performed on the same tumor block generated informative results for other genes that were tested; in 4 cases other sequence analyses yielded a negative result. Additional molecular analyses for all 13 cases are tabulated in Supplementary Table S3 .
VE1 IHC using the Ventana method in CRC
Since the Ventana platform was the method recommended by the VE1 antibody vendor and the majority of previously published reports used the 
To compare our Bond and Ventana VE1 IHC findings in these 92 cases, we plotted the Bond score (x-axis) versus the Ventana score (y-axis) for each individual case ( Figure 2 ). As depicted in the figure, there is a random distribution of individual cases, both BRAF V600E and BRAF wild-type/non-V600E, across VE1 IHC scores using the two different immunohistochemical staining platforms.
Neither BRAF V600E nor wild-type/non-V600E cases demonstrated concordance with respect to their BRAF status by VE1 immunohistochemistry. 
VE1 IHC with
non-V600E melanomas, 63 were negative for the VE1 antibody, representing specificity of 97%.
VE1 IHC in papillary thyroid carcinoma
Our sample size of papillary thyroid carcinoma is limited. Only 36 cases were previously tested by Sequenom or NGS. Of these, 16 harbored BRAF V600E mutation, and 20 were BRAF wild-type. VE1 IHC by the Bond method was performed in 17 cases (9 BRAF V600E and 8 wild-type). All BRAF V600E cases were positive by VE1 IHC, and all BRAF wild-type cases were negative by VE1 IHC, yielding sensitivity and specificity of 100%. VE1 IHC by the Ventana method was performed in 19 cases (7 BRAF V600E and 12 wild-type). All BRAF V600E cases were positive by VE1 IHC, and 11 of 12 BRAF wild-type cases were negative by VE1 IHC, for a sensitivity of 100% and a specificity of 92%. The discordant case was a metastatic papillary thyroid carcinoma involving a lymph node that showed strong VE1 expression by IHC but no mutation by NGS. Given the small amount of tumor present in the tissue tested, it is likely that tumor DNA was diluted with contaminating lymphocyte DNA during DNA extraction, resulting in a false-negative finding on sequencing.
DISCUSSION
In our study, we examined VE1 IHC findings as a surrogate for BRAF V600E mutation status in CRC and compared the results to melanoma and papillary thyroid carcinoma. We believe this is the largest study of its type to date Other published studies examining the concordance between IHC and sequencing for assessing BRAF V600E in CRC are summarized in Table 4 was beyond the scope of this study using retrospective specimens, and thus we cannot determine whether these issues contributed to our observed low sensitivity and specificity. In addition, heat-induced antigen retrieval using an acidic solution was reported to be suboptimal compared to use of a basic solution low tumor volumes and dilution with non-tumoral tissue can produce a falsenegative molecular result. While this may be the case in studies using Sanger sequencing in which the limit of detection is ~20% (i.e. at least 20% of tumor cells must be present in order to reliably detect the mutation of interest) (42), our CAP-accredited, CLIA-certified molecular laboratory has shown the analytical sensitivity of pyrosequencing to be 5% (34) and the analytical sensitivity of both Sequenom (32) and NGS (33) to be ~10%. Moreover, in our study, all 13 cases in which sequence analysis indicated wild-type BRAF and VE1 IHC had either moderate to strong staining in 20% to 70% of tumor cells had adequate tumor for multiple additional molecular analyses (Supplementary Table S3 Multiple studies have suggested that one of the most important advantages of IHC is that tissue-limited samples that could not be analyzed by molecular techniques would be amenable to IHC (20, 21, 23, 24) . In our study, we found significant heterogeneity in VE1 immunohistochemical staining in CRC. with BRAF V600E mutation and found heterogeneous staining in four cases (29%) (20) . Thus, significant sampling error may be encountered when VE1 IHC is performed on a biopsy specimen. In contrast, reliable molecular results may be achieved from limited tissue. Our laboratory has shown that 10 ng of formalinfixed, paraffin-embedded DNA is sufficient to amplify mutation hot-spot regions in 46 genes (including BRAF) using Ion Torrent Personal Genome Machine (NGS) (33). In fact, we routinely perform DNA sequencing on biopsy specimens, including fine-needle aspiration specimens, in our laboratory.
In summary, we performed the largest study to date to evaluate the reliability of VE1 IHC as a surrogate marker for BRAF V600E mutation in CRC.
We found that, in contrast to what has been reported in melanoma and papillary thyroid carcinoma, the sensitivity and specificity of VE1 IHC in CRC are suboptimal, indicating that this technique should not be used to guide therapy and clinical management of patients with CRC. In the era of personalized medicine, more rigorous validation of tests with prognostic and predictive importance is necessary to optimize care for cancer patients. 
